INTRODUCTION {#sec1-1}
============

Bladder cancer has an incidence of 15 cases per 100,000 persons in the global population with more than 60,000 new cases reported each year in the United States alone, and represents the fourth most common malignancy in men and the tenth in women.\[[@CIT1]\] It is the most commontumor of the urinary tract, after prostatic carcinoma, and it is between three- to seven-fold more frequent in males than in females.\[[@CIT2]\] About 90% of bladder malignancies are urothelial carcinomas, characterized by proliferation of the transitional epithelium (transitional cell carcinomas) and in about 25% of cases it is a multifocal disease.

Of particular aetiological importance is a history of exposure to chemical substances, which, as carcinogens or co-carcinogens, may lead to the development of carcinoma with a latency of up to 30 years. Recreational poisons, such as tobacco, have been implicated, and the role of industrial carcinogens has been recognized for a long time.\[[@CIT3]\] Besides chemical substances, other iatrogenic causes include medical radiation treatments of the lower pelvic region. Chronic cystitis has also been suspected, as well as schistosoma haematobium infections which are thought to be involved in squamous cell carcinoma. The cardinal, and first, symptom of bladder carcinoma is usually macrohaematuria. Indeed, any episode of painless macrohaematuria could suggest the presence of malignant urinary tract disease until proven otherwise. The staging of urothelial bladder carcinoma is based on the International Union Against Cancer (UICC) TNM classification, and on tumor cell differentiation (grading). Clinically relevant to prognosis at the time of diagnosis is whether the tumor is superficial, or has already invaded the underlying mucosa, as observed in about 30% of cases.

Bladder cancer is undoubtedly a tumor type that could benefit from screening as early detection has been demonstrated to greatly reduce mortality. In fact, survival is stage-dependent, and the five-year survival for patients with tumors confined to the mucosa is significantly higher than that of patients with muscle-invasive or metastatic cancers.\[[@CIT4]\]

Downstaging of bladder cancer through screening programs was first demonstrated more than ten years ago by Messing and co-workers\[[@CIT5]\] and was recently confirmed in the same case series in a 14-year follow-up.\[[@CIT6]\] In this study, the proportion of muscle-invasive tumors was significantly lower in screened (10%) than in unscreened males (60%). Moreover, whilst 20% of the unscreened population died from bladder cancer during follow-up, no deaths were observed in the group with screening-detected tumors.

The search for and development of an ideal marker for the early detection of bladder cancer has been intensely pursued in recent years, and a spectrum of markers has been identified and investigated. In particular, an ideal diagnostic test should be non-invasive, inexpensive, easy to perform, and the marker evaluated should be detectable in early stage and grade tumors such as *in situ* carcinoma. In addition, the test should be highly accurate to reduce the rate of false positive and negative results.

DIAGNOSTIC TESTS CURRENTLY USED {#sec1-2}
===============================

Imaging techniques such as ultrasound (US), computed tomography (CT), and magnetic resonance imaging (MRI) are widely used for bladder cancer diagnosis. However, due to tumor size and localization they are not accurate enough to detect the majority of tumors, or to correctly distinguish between non-malignant lesions and reactive processes.\[[@CIT7]\] On the other hand, the invasive cystoscopy method is not able to detect tumors which remain below the mucosa surface, such as *in situ* carcinoma, nor to correctly interpret non-specific areas of redness.\[[@CIT7]\] However, notwithstanding these limitations, cystoscopy still represents the gold standard for bladder cancer detection with sensitivity and specificity rates ranging from 70 to 80%.\[[@CIT8]\] Bladder carcinoma recurrs in 70 to 80% of cases, and presents at a more advanced stage in 20 to 30%. A careful and frequent follow-up observation is therefore of paramount importance\[[@CIT9]\] and for this reason cystoscopic examinations are recommended every three months as standard practice.

More than 50 years ago, Papanicolaou and Marshall recognized the importance of a non-invasive technique for the diagnosis and follow-up of bladder carcinoma patients.\[[@CIT10]\] If such a method could also be cost-effective, its introduction as a screening method in at risk subgroups, including persons employed in textile, tannery, chemical, rubber, and pharmaceutical industries, as well as smokers, or in symptomatic individuals, could be useful.\[[@CIT7]\] However, non-invasive methods which are able to compete with cystoscopy in terms of diagnostic accuracy are still not available. For example, urine cytology examination is a simple test practicable in all laboratories, but despite its high specificity, it does not have sufficient sensitivity to accurately diagnose well-differentiated or early stage bladder carcinomas. In fact, while the specificity has been reported to vary from 84 to 100% in case-control studies, and from 93 to 99% in symptomatic patients, the sensitivity varies from 26 to 75% and from 16 to 56%, respectively \[[Table 1](#T0001){ref-type="table"}\]. Moreover, cytologic examination is quite observer dependent, as shown by the high variability of interstudy results \[[Table 1](#T0001){ref-type="table"}\] and for this reason it has become a less important diagnostic tool in recent years.

###### 

Diagnostic accuracy of cytology

                                         Number of cases   Sensitivity (%)   Specificity (%)
  -------------------------------------- ----------------- ----------------- -----------------
  **Case-control studies**                                                   
   Weikert *et al.*\[[@CIT38]\]          400               34                93
   Halling *et al.*\[[@CIT12]\]          265               58                98
   Babjuk *et al.*\[[@CIT22]\]           218               33                100
   Eissa *et al.*\[[@CIT55]\]            200               75                94
   Sarosdy *et al.*\[[@CIT11]\]          176               26                \-
   Eissa *et al.*\[[@CIT26]\]            168               44                100
   May *et al.*\[[@CIT15]\]              166               71                84
   Saad *et al.*\[[@CIT23]\]             120               48                87
   Adb El Gawad *et al.*\[[@CIT21]\]     86                54                100
   Placer *et al.*\[[@CIT13]\]           86                64                86
   Varella-Garcia *et al.*\[[@CIT14]\]   19                43                100
  Symptomatic patients                                                       
   Grossman *et al.*\[[@CIT27]\]         1331              16                99
   Sarosdy *et al.*\[[@CIT20]\]          497               38                \-
   Laudadio *et al.*\[[@CIT19]\]         300               34                93
   Sharma *et al.*\[[@CIT24]\]           278               56                93
   Kavaler *et al.*\[[@CIT45]\]          151               51                98
   Landman *et al.*\[[@CIT25]\]          77                40                94

Tabulated according to size of case-series

NEW MOLECULAR NON-INVASIVE APPROACHES {#sec1-3}
=====================================

The availability of more accurate diagnostic and possibly non-invasive tests has been a major objective pursued intensively in recent years. An ideal diagnostic marker should have both a high sensitivity and specificity, and also be able to detect well-differentiated and early stage tumors. The method must also be simple, and sufficiently inexpensive to facilitate the analysis of a large number of urine samples in a reasonable amount of time.

In recent years, several markers of diagnostic relevance have been identified and a number of reagents directed against molecular targets have been developed commercially \[[Table 2](#T0002){ref-type="table"}\]. The most intensively investigated are chromosome alterations detected by fluorescence *in situ* hybridization (FISH),\[[@CIT11]--[@CIT20]\] urinary human complement factor H related protein (BTA stat and BTA TRAK),\[[@CIT11][@CIT18][@CIT21]--[@CIT25]\] nuclear matrix protein (NMP22),\[[@CIT21][@CIT23]--[@CIT28]\] followed by cytocheratin 8 and 18 fragments (UBC rapid, and UBC immunoradiometric assay, UBC ELISA).\[[@CIT15][@CIT22][@CIT26]\]

###### 

Diagnostic accuracy of different non-invasive assays

                                         Number of cases   Type of assay   Sensitivity (%)   Specificity (%)
  -------------------------------------- ----------------- --------------- ----------------- -----------------
  **Case-control studies**                                                                   
   Halling *et al.*\[[@CIT12]\]          265               FISH            81                96
   Skacel *et al.*\[[@CIT16]\]           120               FISH            85                97
   Placer *et al.*\[[@CIT13]\]           86                FISH            80                85
   Riesz *et al.*\[[@CIT17]\]            55                FISH            87                100
   Varella-Garcia *et al.*\[[@CIT14]\]   19                FISH            87                100
   Halling *et al.*\[[@CIT18]\]          265               FISH            81                100
                                                           BTA stat        78                74
   Sarosdy *et al.*\[[@CIT11]\]          176               FISH            71                100
                                                           BTA stat        50                \-
   Saad *et al.*\[[@CIT23]\]             120               NMP22           81                87
                                                           BTA stat        63                82
   Babjuk *et al.*\[[@CIT22]\]           218               BTA stat        74                87
                                                           BTA TRAK        76                73
                                                           UBC rapid       49                79
                                                           UBC IRMA        70                64
   May *et al.*\[[@CIT15]\]              166               FISH            53                74
                                                           UBC             40                75
   Eissa *et al.*\[[@CIT26]\]            168               NMP22           85                91
                                                           UBC             67                81
   Adb El Gawad *et al.*\[[@CIT21]\]     86                NMP22           91                87
                                                           BTA             100               92
  Symptomatic patients                                                                       
   Sarosdy *et al.*\[[@CIT20]\]          497               FISH            69                78
   Laudadio *et al.*\[[@CIT19]\]         300               FISH            73                65
   Grossman *et al.*\[[@CIT27]\]         1331              NMP22           56                86
   Sharma *et al.*\[[@CIT24]\]           278               NMP22           82                82
                                                           BTA stat        68                82
   Atsü *et al.*\[[@CIT28]\]             82                NMP22           78                66
   Landman *et al.*\[[@CIT25]\]          77                BTA             40                73
                                                           NMP22           81                77

FISH = fluorescence *in situ* hybridization, BTA = bladder tumor antigen, NMP22 = nuclear matrix protein, UBC = urinary bladder cancer Tabulated according to size of case-series within each marker

With regard to the most intensively investigated markers, consistent results have been obtained for FISH, with a sensitivity of approximately 80%, and a specificity between 90 and 100% in case-control studies. However, the test is expensive, cannot be performed in all laboratories, and accuracy strongly decreases when it is used for symptomatic patients. FISH, like cytology, requires specialized personnel to ensure a correct morphologic evaluation. Similar sensitivity and specificity have been reported for NMP22 in case control studies, albeit with lower accuracy, especially in terms of sensitivity in symptomatic patients. For all these molecular tests, sensitivity ranges from 40 to 100% in different case-control studies, and from 40 to 82% in symptomatic patient series. Specificity also varies markedly, from 64 to 100% in the former, and from 65 to 86% in the latter subgroups \[[Table 2](#T0002){ref-type="table"}\].

Moreover, intra-assay variability is often higher than inter-assay variability, indicating a potential lack of standardization of technical aspects and preanalytical phases. Indeed, specific protocols and standards often adopted by individual laboratories determine a wide range of results which are not easily comparable.

TELOMERASE {#sec1-4}
==========

Among the markers most recently proposed to improve diagnostic accuracy, especially in terms of sensitivity, increasing attention has been focused on the role of the ribonucleoprotein, telomerase. This enzyme consists of three subunits: an RNA component (hTR), which acts as a template for DNA replication,\[[@CIT29]\] a telomerase associated protein (TP1)\[[@CIT30]\] of as yet unknown function, and the telomerase reverse transcriptase (hTERT), which is responsible for catalytic activity.\[[@CIT31]\] Telomerase activity (TA) has been detected in almost all malignant cells and tissues, and only very occasionally in normal somatic cells.\[[@CIT32]--[@CIT34]\]

The telomeric repeat amplification protocol assay (TRAP), a polymerase chain reaction (PCR) based method for detection of TA, has been available since 1994.\[[@CIT32]\] The introduction of this method is an important milestone in telomerase research and has become the standard method for studying the diagnostic relevance of this enzyme \[[Table 3](#T0003){ref-type="table"}\].\[[@CIT34]--[@CIT37]\] TA has also been determined qualitatively and quantitatively using modified TRAP assays, for example TRAP scintillation proximity assay, TRAP-ELISA, fluorescent TRAP assay, TRAP hybridization assay, and bioluminescence linked with TRAP. Other methods have focused on the detection of the telomerase subunits, hTR and hTERT, using the reverse transcriptase polymerase chain reaction (RT-PCR). Real-time PCR methods have also permitted a quantitative and reproducible determination of these subunits.\[[@CIT38]\] Expression of the hTERT protein has also been analyzed by immunocytochemistry using anti-hTERT monoclonal\[[@CIT39][@CIT40]\] and polyclonal antibodies.\[[@CIT41]\]

###### 

Diagnostic accuracy of telomerase-based assays

                                       Number of cases   Type of marker                         Sensitivity (%)   Specificity (%)
  ------------------------------------ ----------------- -------------------------------------- ----------------- -----------------
  Case-control studies                                                                                            
   Halling *et al.*\[[@CIT18]\]        265               TA[\*](#T000F1){ref-type="table-fn"}   46                91
   Sanchini *et al.*\[[@CIT37]\]       218               TA[\*](#T000F1){ref-type="table-fn"}   90                88
   Bravaccini *et al.*\[[@CIT47]\]     212               TA[\*](#T000F1){ref-type="table-fn"}   87                66
   Sanchini *et al.*\[[@CIT36]\]       200               TA[\*](#T000F1){ref-type="table-fn"}   92                81
   Saad *et al.*\[[@CIT23]\]           120               TA[\*](#T000F1){ref-type="table-fn"}   84                93
   Fedriga *et al.*\[[@CIT35]\]        106               TA[\*](#T000F1){ref-type="table-fn"}   89                68
   Adb El Gawad *et al.*\[[@CIT21]\]   86                TA[\*](#T000F1){ref-type="table-fn"}   80                95
   Eissa *et al.*\[[@CIT55]\]          200               TA[\*](#T000F1){ref-type="table-fn"}   75                92
                                                         hTERT                                  96                96
                                                         HTR                                    92                89
   Weikert *et al.*\[[@CIT38]\]        400               hTR                                    77                72
                                                         hTERT                                  55                85
  Symptomatic patients                                                                                            
   Kavaler *et al.*\[[@CIT45]\]        151               TA[\*](#T000F1){ref-type="table-fn"}   85                66
   Landman *et al.*\[[@CIT25]\]        77                TA[\*](#T000F1){ref-type="table-fn"}   80                80

TA performed by TRAP assay

ENZYMATIC ACTIVITY {#sec1-5}
==================

TRAP assay {#sec2-1}
----------

The detection of TA in bladder washing and voided urine has been investigated for its diagnostic potential. Since this technique detects TA, and not only the presence of the enzyme, viable cells are a prerequisite. In fact, a possible limitation of the TRAP assay is the potential vulnerability and inactivation of the enzyme by external factors.\[[@CIT7]\] Bladder washings are obtained by mechanical irrigation of the empty urinary bladder using saline solution at physiological pH. However, in native urine, suspended tumor cells are exposed to destructive substances such as proteases, urea, salts and, usually, acid pH, for variable times. All of these factors may lead to early inactivation or degradation of the enzyme that could explain the lack of reproducibility of results among the different studies. Moreover, bladder washings are obtained through the use of a catheter or cystoscope, which are both invasive instruments. For this reason, voided urine has been the most widely used biological sample for the TRAP assay.

The first reported TRAP assay studies were based on qualitative, and thereafter with semi-quantitative TA determinations.\[[@CIT42]\] To obtain more accurate and reliable results, a quantitative TRAP assay was developed in bladder washings and voided urine, based on exponential amplification of the primer-telomeric repeats generated in the telomerase reaction.\[[@CIT36][@CIT43]--[@CIT46]\] Several case-control studies have also confirmed that this test is more accurate in males than females,\[[@CIT36]\] with a higher specificity in younger than older individuals.\[[@CIT37]\] A recent study by the same authors suggested that these results could be due to the presence of inflammatory cells, which are almost always positive to telomerase.\[[@CIT47]\] Furthermore, the diagnostic accuracy of TA was not related to the tumor stage or grade, and was as high in both early stage and low grade tumors, including *in situ* carcinomas,\[[@CIT36]\] in contrast to what has been reported by other authors.\[[@CIT23]\] However, before introducing this test in routine clinical practice, in combination with, or as an alternative to invasive cytoscopy, its potential, in terms of sensitivity and specificity, must be further investigated and defined in a consecutive series of symptomatic individuals.\[[@CIT48]\]

EXPRESSION OF HTR AND HTERT {#sec1-6}
===========================

RT-PCR {#sec2-2}
------

It has been shown that transcriptional regulation of the catalytic component of the telomerase complex is a major determinant in the control of TA.\[[@CIT49][@CIT50]\] Meanwhile, hTR seems to be ubiquitously expressed in most cells,\[[@CIT29][@CIT51]\] independent of enzyme activity. Studies have pointed out that high hTERT mRNA expression is associated with malignancy in many tumor histotypes, and has shown great potential for early cancer detection in body fluids.\[[@CIT7][@CIT46][@CIT52]\] Indeed, the expression of hTERT and hTR mRNA, both in tissues\[[@CIT53]\] and in voided urine samples,\[[@CIT38]\] seems to correlate positively with tumor stage and grade, even if these data have not, as yet, been confirmed.\[[@CIT54]\] Moreover, a good concordance has been shown between mRNA of both telomerase subunits and telomerase activity.\[[@CIT55]\]

Immunocytochemistry {#sec2-3}
-------------------

Many studies have shown that the TRAP assay does indeed have some drawbacks, the most important being the rate of false positives due to the presence of inflammatory non-tumor cells in voided urine and bladder washings.\[[@CIT36][@CIT47]\] It is therefore important to carry out a morphological analysis to identify the true nature of urothelial telomerase expressing cells \[[Figure 1](#F0001){ref-type="fig"}\] and to unmask any false TRAP positives \[[Figure 2](#F0002){ref-type="fig"}\]. The availability of both monoclonal (Mab tel 3 36-10 DIESSE Diagnostica Senese Italy, commercialized by the Alexis Corporation, Lausanne, Switzerland; NCL-hTERT Novocastra, Newcastle- upon Tyne UK) \[[Figure 1](#F0001){ref-type="fig"}\] and polyclonal antibodies (TERT H-231: sc-7212, Santa Cruz Biotechnology Inc, Santa Cruz, CA, USA; hTERT EST21A Alpha Diagnostic International, San Antonio, TX), able to detect hTERT protein expression, has opened up the possibility of studying the different cell components. Up to now very few diagnostic studies on urine have been conducted using anti-hTERT antibodies; some have used freshly-filtered cytological samples,\[[@CIT36]\] while others have utilized sections of urine cells from paraffin-embedded blocks.\[[@CIT56]\] Depending on the antibody used, nuclear, nucleolar or cytoplasmic staining singly or in combination, were detected. Both nuclear and cytoplasmic hTERT positivity has been observed previously.\[[@CIT40]\] Indeed, the authors hypothesized that the positivity in the cytoplasm could be due to either a disruption of the normal hTERT nuclear translocation process during malignant transformation, or to the existence of post-transcriptional/post-translational modes of telomerase regulation such as hTERT phosphorylation, which are responsible for telomerase structure and activity. Furthermore, since the enzyme forms a large dimer/multidimer complex, correct assembly of the different components is important for catalytic activity. Almost all published studies have consistently shown the frequent or almost total presence of positivity in inflammatory cells \[[Figure 2](#F0002){ref-type="fig"}\]. In addition, an accurate analysis of anti hTERT antibody (tel 3 36-10) determinations\[[@CIT36]\] has shown a higher fraction of immunoreactive inflammatory and non bladder epithelial cells in women than in men. This finding has been suggested to be due to the shorter female urethra, which favors the entrance of bacteria into the bladder and could, at least in part, explain the increased number of false positive results.\[[@CIT47]\] The diagnostic accuracy of the TRAP assay could be improved by considering the percentage of non-tumor hTERT-expressing cells in the same urine sample. However, it still needs to be demonstrated that the two markers are equivalent. In fact, there is evidence that some tissues may be positive for hTERT mRNA, but not for TA.\[[@CIT57]\]

![Immunoreactivity of bladder tumor cells to Mab anti-hTERT tel 3 36-10 Diesse](IJU-25-40-g001){#F0001}

![Immunoreactivity of inflammatory cells to Mab anti-hTERT tel 3 36-10 Diesse](IJU-25-40-g002){#F0002}

CONCLUSIONS {#sec1-7}
===========

The importance of early diagnosis for bladder cancer has undoubtedly been demonstrated. Most of the diagnostic approaches currently used are either invasive or do not assure sufficient accuracy, especially in terms of sensitivity. Among the non-invasive approaches, urine cytology presents major limitations in detecting tumors of low stage and grade. An ideal test should be non-invasive, accurate, easy to perform and reproducible. Moreover, due to the relatively low incidence of bladder tumors in the general population, the test should be used to screen professionally high-risk groups, or symptomatic patients, 5 to 10% of which present with bladder cancer, to be advantageous in cost/benefit terms.\[[@CIT48]\] The urine telomerase assay satisfies many of these requirements, providing a good sensitivity and specificity in case-control studies and a somewhat lower but acceptable sensitivity and specificity in the few studies performed on symptomatic patients. The main limitation of this marker is the presence of false positives due to the telomerase activity (TA) inherent within inflammatory and/or non-urothelial cells in urine. Consequently, an *in situ* analysis would appear essential to reduce the number of false TRAP positive results.\[[@CIT36][@CIT47]\] Evaluation of the intrinsic RNA component (hTR) by *in situ* hybridization, as well as immunocytochemical assessment of hTERT subunit expression, have both been applied as surrogate markers of TA. However, hTR evaluation by *in situ* hybridization makes quantitative analysis difficult and not all pathology laboratories are suitably equipped to perform this method. In contrast, the availability of anti-hTERT antibodies has opened up the possibility to easily identify the different cellular components of urine. Nonetheless, there is some doubt on the feasibility of immunocytochemical hTERT protein detection since the presence of the protein is not necessarily associated with its activity.\[[@CIT40]\]

Urine TA appears to show great potential as an early diagnostic marker, particularly if used in high-risk professional groups\[[@CIT48]\] and symptomatic patients. In any case, further prospective studies are needed to fully demonstrate its suitability as a first-line diagnostic tool. Other specific markers should also be investigated, for example, chromosomal alterations by fluorescence *in situ* hybridization that have maximum specificity, and could therefore be a second level diagnostic approach for unmasking false positive TRAP results and increasing the diagnostic accuracy.
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